Gilead Sciences share price logo

Gilead Sciences

NASDAQ: GILD

Mega Cap

$168.98

-1.28

(-0.75%)

as on

Gilead Sciences Stock Performance

as on November 19, 2026 at 7:59 am IST

  • Day's Low

    Day's High

    $167.36
    $170.50
    downward going graph

    0.96%

    Downside

    0.90%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $116.88
    $176.58
    downward going graph

    30.83%

    Downside

    4.50%

    Upside

    downward going graph

Gilead Sciences share price movements today

Previous Close
$170.26
Open
$168.78
Volume
2.2M
Market Cap
$211.2B
Dividend Yield
1.91%
Day's Low - High
$167.36 - $170.50
52 Week Low - High
$116.88 - $176.58

Gilead Sciences Historical Returns

1 Month Return
+ 10.39 %
3 Month Return
+ 14.49 %
1 Year Return
+ 31.94 %
3 Year Return
+ 123.96 %
5 Year Return
+ 146 %

Gilead Sciences Stock Fundamentals & Key Indicators

Check Gilead Sciences market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$211.2B

EPS (TTM)

-3.1

Dividend Yield

1.91%

Quarterly Earnings Growth YOY

-0.20%

PE Ratio (TTM)

-54.72

Industry PE ratio

21.86

PEG Ratio

0.41

EBITDA

1.3B

Revenue (TTM)

31.0B

Profit Margin

79.93%

Return On Equity TTM

-21.74%

Gilead Sciences vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Gilead Sciences with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$211.2B146.00%-54.7279.93%1.91%
StrongBuy$1.3T430.40%45.5483.63%0.49%
StrongBuy$520.7B150.12%50.0673.72%2.35%
Buy$680.2B71.61%42.3067.56%1.87%
StrongBuy$286.8B60.70%25.6177.59%1.76%

Stock Returns calculator for Gilead Sciences Stock including INR - Dollar returns

The Gilead Sciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Gilead Sciences investment value today

Current value as on today

₹1,39,227

Returns

₹39,227

(+39.23%)

Returns from Gilead Sciences Stock

₹31,943 (+31.94%)

Dollar Impact

₹7,283 (+7.28%)

Analyst Recommendation on Gilead Sciences Stock

Based on 17 analysts

BUY

88.24%

Buy

11.76%

Hold

0.00%

Sell

Based on 17 analysts, 88.23529411764706% of analysts recommend a 'BUY' rating for Gilead Sciences. Average target price of $175.92

Gilead Sciences Share Price Target

Get share price movements and forecasts by analysts on Gilead Sciences.

What analysts predicted

3.94%UPSIDE

Target Price

$175.92

Current Price

$168.98

Analyzed by

17 Analysts

High

$200

Target

$175.92

Low

$131

Gilead Sciences target price $175.92, a slight upside of 3.94% compared to current price of $168.98. According to 17 analysts rating.

Indian Investors' Interest in Gilead Sciences Stock

Search interest for Gilead Sciences Stock has increased by 66% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:66% versus previous 30 day period

Gilead Sciences Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
6,953
7,545
7,569
6,667
7,081
7,769
7,925
6,960
7,803
8,300
Gross Profit
5,409
5,971
5,988
5,127
5,580
6,200
6,301
5,515
6,224
6,729
Operating Income
2,644
888
2,452
2,237
2,474
3,327
1,984
2,692
2,539
3,480
EBITDA
2,984
1,884
3,109
2,605
3,374
4,583
3,018
3,509
-9,309
4,072
Interest Expense
237
238
249
260
254
256
254
240
247
269
Depreciation
694
690
693
696
691
686
687
689
698
740
Income Before Tax
2,053
956
2,167
1,649
2,429
3,641
2,077
2,580
-10,254
3,063
Income Tax Expense
438
-297
385
334
468
589
-105
559
242
634
Net Income
1,614
1,253
1,783
1,315
1,960
3,052
2,183
2,021
-10,496
2,429
Net Profit Margin
77.79%
79.14%
79.11%
76.90%
78.80%
79.80%
79.51%
79.24%
79.76%
81.07%

Gilead Sciences Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
26,107
22,127
22,449
24,689
27,305
27,281
27,116
28,754
29,442
Gross Profit
21,736
17,274
17,774
20,117
20,704
21,624
20,618
22,503
23,208
Operating Income
14,124
8,200
4,287
4,071
9,918
7,330
7,605
1,662
10,022
EBITDA
15,933
10,305
7,559
4,133
11,329
8,852
10,496
4,434
13,580
Interest Expense
1,118
1,077
995
984
1,001
935
944
977
1,024
Depreciation
1,286
1,429
1,404
1,480
2,050
2,103
2,693
2,767
2,760
Income Before Tax
13,529
7,799
5,160
1,669
8,278
5,814
6,859
690
9,796
Income Tax Expense
8,885
2,339
-204
1,580
2,077
1,248
1,247
211
1,286
Net Income
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
Net Profit Margin
83.26%
78.07%
79.18%
81.48%
75.82%
79.26%
76.04%
78.26%
78.83%

Gilead Sciences Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
1,614
1,253
1,783
1,315
1,960
3,052
2,183
2,021
-2,021
2,430
Operating Cash Flow
1,325
4,309
2,975
1,757
827
4,108
3,326
2,544
3,573
5,036
Investing Cash Flow
-307
-710
-225
-415
-2,116
-427
-1,835
1,770
-10,347
-243
Financing Cash Flow
-2,953
-1,379
2,260
-3,426
-1,567
-1,489
-1,263
-4,239
2,344
-1,528
Change in Cash
-1,946
2,265
4,954
-2,065
-2,782
2,186
234
64
-4,449
3,261

Gilead Sciences Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
4,644
5,460
5,364
123
6,201
4,592
5,665
480
8,510
Operating Cash Flow
11,898
8,400
9,144
8,168
11,384
9,072
8,006
10,828
10,019
Investing Cash Flow
-16,069
14,355
-7,817
-14,615
-3,131
-2,466
-2,265
-3,449
-4,793
Financing Cash Flow
3,393
-12,318
-7,634
770
-8,877
-6,469
-5,125
-3,433
-7,745
Change in Cash
-641
10,352
-6,309
-5,634
-659
74
673
3,906
-2,427

Global Institutional Holdings in Gilead Sciences

Check out the Institutions with significant holdings in Gilead Sciences.

Funds
Holdings
Shares Held
BlackRock, Inc.
10.10%
125246865
Vanguard
8.42%
104493311
VANGUARD INDEX FUNDS
6.84%
84857316
iShares
6.73%
83445763
SPDR
4.16%
51536951

Gilead Sciences News & Key Events

  • img

    Today's Timeline - 12 November

    Thu, 07:11 PM

    -

    Gilead collaborates with TelevisaUnivision for HIV prevention awareness during the Latin GRAMMY Awards.

    Thu, 07:21 PM

    -

    Argus raises Gilead's price target to $190, maintaining a Buy rating after strong Q3 results.

    Thu, 09:50 PM

    -

    Gilead's HIV business shows strong growth, with better-than-expected Q3 results driven by key therapies.

  • img

    Today's Timeline - 12 November

    Fri, 01:37 AM

    -

    Gilead's shares outperform industry; challenges include competition and pricing pressure despite strong HIV portfolio.

Insights on Gilead Sciences

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Gilead Sciences, Inc. has shown a significant improvement in its net profit over the last two quarters. The company's net profit increased from a loss of $10.49 billion to a profit of $2.42 billion. This represents an average growth rate of 532.1% per quarter.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Gilead Sciences, Inc. has experienced positive revenue growth over the past three quarters. Their revenue increased from $6.95 billion to $8.3 billion, representing an average growth of 8.4% per quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, GILD stock has moved up by 15.4%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GILD has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Merck & Co., Inc. has given 50.8% return, outperforming this stock by 17.9%

About Gilead Sciences

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
OrganisationGilead Sciences
Headquarters333 Lakeside Drive, Foster City, CA, 94404, US
IndustryDrug Manufacturers - General
CEODaniel O'Day

Key Management of Gilead Sciences

Name

Title

Dr. Linda Slanec Higgins Ph.D.

Senior Vice President of Research, Innovation & Portfolio

Dr. Flavius Martin M.D.

Executive Vice President of Research

Ms. Erin E. Burkhart

Senior VP, Controller & Chief Accounting Officer

Ms. Jacquie Ross C.F.A.

Senior Vice President of Treasury & Investor Relations

Ms. Jyoti K. Mehra

Executive Vice President of Human Resources

Dr. Dietmar P. Berger M.D., Ph.D.

Chief Medical Officer

Ms. Keeley M. Cain Wettan

Executive VP, General Counsel of Legal & Compliance and Secretary

Mr. Daniel Patrick O'Day

Chairman & CEO

Mr. Andrew D. Dickinson

Executive VP & CFO

Ms. Johanna Mercier

Chief Commercial & Corporate Affairs Officer

FAQs

What is Gilead Sciences share price today?

Gilead Sciences share price today is $168.98 as on at the close of the market. Gilead Sciences share today touched a day high of $170.50 and a low of $167.36.

What is the 52 week high and 52 week low for Gilead Sciences share?

Gilead Sciences share touched a 52 week high of $176.58 on and a 52 week low of $116.88 on . Gilead Sciences stock price today i.e. is closed at $168.98,which is 4.30% down from its 52 week high and 44.58% up from its 52 week low.

What is Gilead Sciences's market capitalisation today?

Gilead Sciences market capitalisation is $0.21T as on .

How to invest in Gilead Sciences Stock (GILD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Gilead Sciences on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Gilead Sciences Stock (GILD) from India?

Indian investors can start investing in Gilead Sciences (GILD) shares with as little as ₹93.44000244140625 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹934.40 in Gilead Sciences stock (as per the Rupee-Dollar exchange rate as on ). Based on Gilead Sciences share’s latest price of $168.98 as on November 19, 2026 at 2:29 am IST, you will get 0.0592 shares of Gilead Sciences. Learn more about fractional shares .

What are the returns that Gilead Sciences has given to Indian investors in the last 5 years?

Gilead Sciences stock has given 146% share price returns and 26.65% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?